Frankl believed that life can be made meaningful in a three-fold way: through what we give (in terms of creative work), from ...

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Ozempic could help patients with advanced Alzheimer’s disease, scientists believe. Trials are underway examining the impact ...

Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Alzheimer's Disease.

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

In the past month and a half, four individuals with dementia have been found dead in Georgia after wandering away from home, ...

Dr Karan Rajan, an NHS surgeon and University of Sunderland lecturer, has shared his thoughts on 'menstrual blood-derived ...

新型生物标志物的发现和新型治疗药物的问世， 标志着阿尔茨海默病在诊断与治疗方面有了突破性的进展 ，相信在未来的临床研究中可能会发现准确性更高的生物标志物和疗效更确切、不良反应更少、更加便捷的药物，从而 延缓阿尔茨海默病的病情进展及改善患者的生活质量 ...

Ta-1505 is under clinical development by Merck and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate ...

Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...

Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.

The presence of CVD may increase the risk of developing dementia among older patients with RA, though CVD was not found to ...